Cambridge, Mass. • 617-264-1800 • www.helicosbio.com
Exchange and Ticker: Nasdaq: HLS
Filing Range: 5.40M shares @ $13.00 to $15.00
Offering Price: $9.00
Close on First Day: $8.47
Offering Size: $48.60M
Shares Outstanding: 20,519,975M
Underwriter: UBS Investment Bank
Co-managers: Pacific Growth Equities Inc./ Leerink Swann & Co.
Company Counsel: Goodwin Procter LLP
Manager Counsel: Dewey Ballantine LLP
Auditor: Pricewaterhouse Coopers LLP
Market Capitalization on 5/31/07: $172.37M
Close price at current month end: $8.40
Operates as a life sciences company that develops genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. The company’s first commercial product, the HeliScope, is designed to enable ultra-high-throughput genetic analysis based on the direct sequencing of single molecules of DNA or single copies of RNA. Competitors include the Applied Biosystems division of Applera Corp., Beckman Coulter Inc., the Amersham Biosciences business of General Electric Company, Affymetrix Inc., Agilent Technologies, others.
Atlas Venture, Flagship Ventures, Highland Capital Partners, MPM Capital, Versant Ventures.
Source: Thomson Financial